Another Rally from FED minutes…except biotech
10/8/15 … BIOTECH-Another test near 2015 lows in early AM ; choppy downtrend but look for a bottoming process as market is turning up toward close:
IBB at 306 down slightly after reversal
XBI down 1.7% to 63.3
XLV now green
10/5 9 AM …Rally Should Continue for Third Day Today-Futures Up, Global Markets Up
After close: http://fixzoneni.co.uk/nproject/samsung-galaxy-note-5-screen-replacement-lisburn/ 1.83% rally on http://kidschanceofne.org/lostpassword Dow and S&P but healthcare lags.
The healthcare sector lagged the huge move in stocks today with the XLV up only 0.26%. Biotechs started off strong but fell shortly after the opening and the IBB ended down 0.74%. Blame pricing concerns so wait for earnings later this month before adding to positions.The smaller cap XBI recovered closing up 0.79% at $66. So we are 4.5% off recent biotech bottom but still in a cautious mode.
The diagnostics and tools are also being hurt by slower growth and today Illumina (ILMN) was down 14% after hours on disappointing guidance.
http://soloways.ca/wp-json/oembed/1.0/embed?url=http://soloways.ca/contact-5/ 10/2/Huge Rally On Early Morning Reversal
The market opened down then abruptly took off with NASDAQ taking the lead. Biotechs followed yesterday’s rally with the IBB up 3.47% to $315.5 and the XBI up 4.89% to$65.5. The healthcare sector was up 1.92%, and almost all biotech stocks we track were up big. We will review our portfolio YTD over the weekend but the big winners appear to be the riskier momentum stocks as can be seen with the XBI move. Mid caps were up big: CLVS, SGEN, VRTX. Keep in mind that this is traders and fund managers bottom fishing after the huge decline. However it is encouraging that there is a lot money out there coming back into the sector.
10/1/15 Update… Traders Jump in Today
The biopharma stocks had a better tone today favoring large caps. Among the large caps the best movers were ABBV, AMGN, CELG, and REGN. Celgene (CELG) had bullish talk on CNBC today. Incyte (INCY) rocketed up 6.89%. Keep in mind that Q3 earnings begin this month around 10/20. The IBB had two green days off bottom. Same for XBI and FBT. We need five days of trading to call the intermediate bottom.
Bear Market Mentality Hits Biotech
FBT 110.5 down 1.23% YTD
IBB $296 down 2.3% YTD
XBI $61.8 flat YTD
Fidelity Select Biotech Fund (FBIOX) $212 down 4% YTD
Review Previous Articles on Biotech Market Trends
The vicious three month sell-off with the IBB down 20% over one month in the six year bull market has created so much psychological damage that a bear market could prevail at least until third quarter earnings gives us clarity. Add new positions with caution keeping in mind that selling prevails.Biotech stocks have been driven to extreme valuations by large hedge funds, investment banks and mutual funds who are primarily momentum investors with huge cash coffers.
We will continue with the “Biotech Market Trends” series adding some new elements to our model now that we have entered a bear market. Four out of five market trends turned negative as we wait earnings in October.The drivers of the 5 year biotech bull market have been: strength in the healthcare sector, M&A, growth from product sales and positive clinical developments. Now we have a change in fundamental factors to consider such as the following:
- The healthcare sector (XLV) and biotech does not have relative immunity to macro economic news and the overall market and certainly is not considered defensive. Biotech and healthcare stocks are now a laggard sector due a scary change in sentiment. Political uncertainty and a FED decision creates a pall that inhibits buyers.
- Pricing was a “sell” catalyst but five-year returns of over 232% drove profit taking on a massive scale.
- Looking ahead toward 2016, M&A may slow as valuations will be scrutinized and the potential for funding will slow with higher interest rates and a nervous high yield bond market. Our biggest winners in 2014-15 were buyouts: Astex (ASTX), Cubist (CBST) and Pharmacyclics (PCYC).
- Valuations now do matter and pipelines may be downgraded to a higher risk level.Emerging companies need to be concerned about long-term cash requirements.
- Life Science ETFs have created more volatility with rapid fire trading long and short.
- Time can cure a bear market and bullish seasonality is ahead. Wait for more clarity and buying interest.
We will not review our Biopharmaceutical Portfolio for new buys until we see a turnaround in technicals or positive earnings announcements for large caps.The following Rayno Biopharma stocks are up YTD as of 9/28: CLVS up 61%, FCSC up 51.7%, GILD up 3.1%, REGN up 12.1% and SGEN up 16%. Most others are down or flat. Stock picking will be more important with sector weakness.
We are hopeful that a Q4 rally will offer some recovery from this bear market turn. Retail investors and generalist funds are likely to avoid the sector until a solid trend develops. The large number of huge specialized funds would need to step in to reverse the course. At the bottom of the last bear market in biotech valuations were at venture capital levels but revenues from the major companies were still very low and most large cap biotech companies are on a solid financial footing.
Biotech stocks are prone to bubble behavior for many reasons primarily because medical breakthroughs such as molecular medicine and genomics are exciting with huge product potential. Low interest rates and fast money created speculative momentum which now has ebbed. In 2012 nobody knew about the bull market in biotech stocks and its underpinnings,but now all investors know about the bear market.